Teva Pharmaceuticals
TEVA
540 hedge funds and large institutions have $16.2B invested in Teva Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 87 funds opening new positions, 177 increasing their positions, 160 reducing their positions, and 48 closing their positions.
81% more first-time investments, than exits
New positions opened: 87 | Existing positions closed: 48
60% more funds holding in top 10
Funds holding in top 10: 10 → 16 (+6)
41% more capital invested
Capital invested by funds: $11.5B → $16.2B (+$4.73B)
11% more repeat investments, than reductions
Existing positions increased: 177 | Existing positions reduced: 160
7% more funds holding
Funds holding: 507 → 540 (+33)
0.74% less ownership
Funds ownership: 66.24% → 65.51% (-0.74%)
20% less call options, than puts
Call options by funds: $614M | Put options by funds: $765M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
PointState Capital
New York
|
+$136M |
| 2 |
Millennium Management
New York
|
+$113M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$83.9M |
| 4 |
Citigroup
New York
|
+$81.3M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$76.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$330M |
| 2 |
HCM
Highfields Capital Management
Boston,
Massachusetts
|
-$206M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$173M |
| 4 |
NC
Northern Cross
Boston,
Massachusetts
|
-$40.8M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$39.8M |
TEVA Hedge Fund Activity: Q2 2018 in Review
540 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q2 2018, worth a combined $16.2B — up 41% from $11.5B a quarter earlier.
Buyers outnumbered sellers: 87 funds opened new TEVA positions and 48 closed out — a net gain of 39 holders — while 177 added to existing stakes and 160 trimmed.
The largest buyer was PointState Capital, opening a new position worth an estimated $136M. The largest seller was JP Morgan Chase, cutting an estimated $330M.
- 540 institutional investors held Teva Pharmaceuticals (TEVA) as of Q2 2018, up from 507 in Q1 2018.
- Funds reported $16.2B of Teva Pharmaceuticals stock for Q2 2018, up 41% quarter-over-quarter.
- 87 funds opened new Teva Pharmaceuticals positions in Q2 2018 and 48 closed out, a net change of +39 holders.
- The largest Teva Pharmaceuticals buyer in Q2 2018 was PointState Capital, an estimated $136M added.
- The largest Teva Pharmaceuticals seller in Q2 2018 was JP Morgan Chase, an estimated $330M sold.
Based on aggregated 13F filings for Q2 2018.